Panobinostat

Panobinostat

File:Panobinostat structure.svg
Systematic (IUPAC) name
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
Identifiers
CAS Number	404950-80-7
ATC code	none
PubChem	CID 6918837
Chemical data
Formula	C21H23N3O2
Molar mass	349.42622 g/mol[[]]

Panobinostat (LBH-589) is an experimental drug developed by Novartis for the treatment of cancer. As of December 2008, it is being tested against cutaneous T cell lymphoma (CTCL), chronic myelogenous leukemia, myelodysplastic syndromes, breast cancer, prostate cancer and other types of malignant disease in a number of Phase II and III clinical trials, for example a Phase III study for CTCL.

Panobinostat has been found to synergistically act with sirolimus to kill pancreatic cancer cells in the laboratory in a Mayo Clinic study. In the study, investigators found that this combination destroyed up to 65 percent of cultured pancreatic tumor cells. The finding is significant because the three cell lines studies were all resistant to the effects of chemotherapy – as are many pancreatic tumors.

Mechanism of action

Panobinostat inhibits one or more of the histone deacetylase enzymes, a mechanism leading to apoptosis of malignant cells via multiple pathways.

See also

• Histone deacetylase inhibitor

References

es:Panobinostat